Vaginal Candidiasis

Phase III trial of Hyphanox begins

Published in Anti-Infectives Week, March 15th, 2004

Barrier Therapeutics, Inc., announced that it has begun enrolling patients in a phase III clinical trial for Hyphanox, its new 200 mg tablet formulation of the antifungal agent itraconazole, in patients with vaginal candidiasis.

The clinical trial will compare the efficacy of a single dose of Hyphanox, formerly referred to as Sporamelt, to a single 150 mg dose of the antifungal fluconazole, a currently available standard oral treatment. A 150 mg tablet of fluconazole for the treatment of vaginal candidiasis is currently sold in the United States by Pfizer, Inc., under the brand name Diflucan.

Barrier expects to enroll approximately 900 patients at 40...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Anti-Infectives Week

Source: Anti-Infectives Week (2004-03-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry